New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer

Sunday, March 1st at 7:00pm ET, Alexander Drilon, MD joined ALKtALK to present and discuss the latest data on neladalkib (NVL-655). The conversation included a review of emerging efficacy and safety data, along with discussion of how promising therapies move from clinical trials toward broader patient access. 

Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, including research focused on ALK-positive cancers. 

Press PLAY to be informed and empowered by a data-driven conversation focused on where the science is now and where it may be headed next.

Whether you are newly diagnosed, in treatment, or supporting someone you love, we invite you to view this important ALKtALK and stay connected to the research shaping our community.

#ALKPositive #ALKtALK #LungCancerResearch #MoreResearchMoreTime